MRTX Mirati Therapeutics Inc.

76.38
+0.86  (+1%)
Previous Close 75.52
Open 74.94
Price To Book 9.7
Market Cap 2753279560
Shares 36,047,127
Volume 571,435
Short Ratio
Av. Daily Volume 642,214

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 update at SITC November 2018 - 5/29 partial responses.
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 initial data 2H 2019.
Sitravatinib and Nivolumab
Renal cell carcinoma (RCC)
Phase 3 trial to be initiated 2Q 2019
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 1b initial data due 2H 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 1/2 update due 2H 2019.
MRTX849
Solid tumors
Phase 2 initial data 2H 2019.
Sitravatinib
Urothelial Carcinoma (Bladder)

Latest News

  1. Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
  2. Here's Why Mirati Therapeutics Is Surging Today
  3. What's Triggering The Rise In Mirati Shares?
  4. Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock
  5. What You Must Know About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Beta Value
  6. Mirati: 1Q Earnings Snapshot
  7. Mirati Therapeutics Reports First Quarter 2019 Financial Results
  8. Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ?
  9. Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
  10. The Mirati Therapeutics (NASDAQ:MRTX) Share Price Has Gained 287%, So Why Not Pay It Some Attention?
  11. Mirati Therapeutics To Present At Upcoming Healthcare Conferences
  12. Mirati Therapeutics Reports Fourth Quarter Financial Results
  13. Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results
  14. Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
  15. Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
  16. Here's Why Mirati Therapeutics Jumped 55.8% in January
  17. Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics
  18. How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares?
  19. The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
  20. Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares